help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guedez, L.
Right arrow Articles by Stetler-Stevenson, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guedez, L.
Right arrow Articles by Stetler-Stevenson, W. G.
(American Journal of Pathology. 2001;158:1207-1215.)
© 2001 American Society for Investigative Pathology


Short Communications

Tissue Inhibitor of Metalloproteinase-1 Alters the Tumorigenicity of Burkitt’s Lymphoma via Divergent Effects on Tumor Growth and Angiogenesis

Liliana Guedez*, Andrew J. McMarlin*, Douglas W. Kingma{dagger}, Teresa A. Bennett*, Maryalice Stetler-Stevenson{dagger} and William G. Stetler-Stevenson*

From the Extracellular Matrix Section *
and the Flow Cytometry Unit,{dagger}
Laboratory of Pathology, Division of Clinical Sciences National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma cells and EBV-infected B cells elicit humoral factors that inhibit tumor-induced angiogenesis, resulting in tumor necrosis and regression. Of the chemokine factors identified in association with this growth behavior, none have induced complete tumor regression. We have previously identified tissue inhibitors of metalloproteinase (TIMP)-1 in various B cell lymphoma cell lines. Here we show that induction of TIMP-1 expression in an EBV-negative Burkitt’s lymphoma cell line results in a biphasic, in vivo tumor growth pattern in the nude mouse that is essentially identical to EBV-positive Burkitt’s lymphoma cell lines. The initial effect of TIMP-1 is to enhance tumor growth, consistent with the reported anti-apoptotic effect of TIMP-1 on B cell growth. Tumor necrosis and regression then follow the initial period of rapid, increased tumor growth. Only microscopic foci of residual, proliferating tumor cells are observed on biopsy of the tumor site. This latter effect is mediated by TIMP-1 inhibition of an angiogenic response within the developing tumor mass, as demonstrated by immunostaining and microvessel counts. These findings suggest that TIMP-1 is an important mediator of the in vivo growth properties of EBV-positive Burkitt’s lymphoma.





This article has been cited by other articles:


Home page
Sci SignalHome page
W. G. Stetler-Stevenson
Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities
Sci. Signal., July 8, 2008; 1(27): re6 - re6.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Lipton, K. Leitzel, H. A. Chaudri-Ross, D. B. Evans, S. M. Ali, L. Demers, P. Hamer, S. Brown-Shimer, K. Pierce, V. Gaur, et al.
Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer
J. Clin. Oncol., June 1, 2008; 26(16): 2653 - 2658.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
Y.-S. Kim, S. Y. Hwang, H.-Y. Kang, H. Sohn, S. Oh, J.-Y. Kim, J. S. Yoo, Y. H. Kim, C.-H. Kim, J.-H. Jeon, et al.
Functional Proteomics Study Reveals That N-Acetylglucosaminyltransferase V Reinforces the Invasive/Metastatic Potential of Colon Cancer through Aberrant Glycosylation on Tissue Inhibitor of Metalloproteinase-
Mol. Cell. Proteomics, January 1, 2008; 7(1): 1 - 14.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev, October 1, 2007; 87(4): 1285 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Kopitz, M. Gerg, O. R. Bandapalli, D. Ister, C. J. Pennington, S. Hauser, C. Flechsig, H.-W. Krell, D. Antolovic, K. Brew, et al.
Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling
Cancer Res., September 15, 2007; 67(18): 8615 - 8623.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. Dien, H. M. Amin, N. Chiu, W. Wong, C. Frantz, B. Chiu, J. R. Mackey, and R. Lai
Signal Transducers and Activators of Transcription-3 Up-Regulates Tissue Inhibitor of Metalloproteinase-1 Expression and Decreases Invasiveness of Breast Cancer
Am. J. Pathol., August 1, 2006; 169(2): 633 - 642.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D.-W. Seo, H. Li, C.-K. Qu, J. Oh, Y.-S. Kim, T. Diaz, B. Wei, J.-W. Han, and W. G. Stetler-Stevenson
Shp-1 Mediates the Antiproliferative Activity of Tissue Inhibitor of Metalloproteinase-2 in Human Microvascular Endothelial Cells
J. Biol. Chem., February 10, 2006; 281(6): 3711 - 3721.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A Noel, C Maillard, N Rocks, M Jost, V Chabottaux, N E Sounni, E Maquoi, D Cataldo, and J M Foidart
Membrane associated proteases and their inhibitors in tumour angiogenesis
J. Clin. Pathol., June 1, 2004; 57(6): 577 - 584.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A.-S. Schrohl, M. N. Holten-Andersen, H. A. Peters, M. P. Look, M. E. Meijer-van Gelder, J. G. M. Klijn, N. Brunner, and J. A. Foekens
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer
Clin. Cancer Res., April 1, 2004; 10(7): 2289 - 2298.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-S. Rhee, R. Diaz, L. Korets, J. G. Hodgson, and L. M. Coussens
TIMP-1 Alters Susceptibility to Carcinogenesis
Cancer Res., February 1, 2004; 64(3): 952 - 961.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
T. E. Curry Jr. and K. G. Osteen
The Matrix Metalloproteinase System: Changes, Regulation, and Impact throughout the Ovarian and Uterine Reproductive Cycle
Endocr. Rev., August 1, 2003; 24(4): 428 - 465.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
A.-S. Schrohl, I. J. Christensen, A. N. Pedersen, V. Jensen, H. Mouridsen, G. Murphy, J. A. Foekens, N. Brunner, and M. N. Holten-Andersen
Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer
Mol. Cell. Proteomics, March 1, 2003; 2(3): 164 - 172.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Zhang, R. C. M. Simmen, F. J. Michel, G. Zhao, D. Vale-Cruz, and F. A. Simmen
Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes
J. Biol. Chem., August 9, 2002; 277(33): 29999 - 30009.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. Huang, M. Van Arsdall, S. Tedjarati, M. McCarty, W. Wu, R. Langley, and I. J. Fidler
Contributions of Stromal Metalloproteinase-9 to Angiogenesis and Growth of Human Ovarian Carcinoma in Mice
J Natl Cancer Inst, August 7, 2002; 94(15): 1134 - 1142.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Pepper
Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis
Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1104 - 1117.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Yan and M. A. Moses
A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma
Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society for Investigative Pathology.